This systematic review examined the measurement properties of the 6-min walk test
(6MWT), incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT) in …

Objective Pulmonary hypertension (PH) is a frequent and life‐limiting complication of
systemic sclerosis (SSc). However, data on survival rates and their evolution over time, as …

Pulmonary arterial hypertension (PAH) is the leading cause of death in systemic sclerosis
(SSc) and affects up to 12% of all patients with SSc, with a 50% mortality rate within 3 years …

Rationale: Pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) has a
poorer prognosis compared with other forms of PAH for reasons that remain unexplained …

There is a need for clinical trial end-points to better assess how patients feel and function, so
that interventions can be developed which alleviate symptoms and improve quality of life …

Lung ailments in rheumatic diseases present unique challenges for diagnosis and
management and are a source of significant morbidity and mortality for patients. Unlike the …

Dyspnoea, fatigue, reduced exercise tolerance, peripheral muscle dysfunction and mood
disorders are common features of many chronic respiratory disorders. Pulmonary …

Background Little is understood about the characteristics of dyspnea in patients with
interstitial lung disease (ILD), and its severity is likely influenced by multiple factors …

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and
mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies …

Rationale: Studies suggest that patients with connective tissue disease–associated
pulmonary arterial hypertension (CTD-PAH) have a poorer treatment response to therapies …